GT Biopharma Q4 Net Loss $(2.96)M Vs $(5.58)M Loss Last Year; Cash Of ~$14M As Of December 31, 2023, Provides Sufficient Runway To Fund Operations Into 2025
GT Biopharma Q4 Net Loss $(2.96)M Vs $(5.58)M Loss Last Year; Cash Of ~$14M As Of December 31, 2023, Provides Sufficient Runway To Fund Operations Into 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.